3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
25
Observational
1
Sponsor
Conditions
Breast Neoplasms
112
Neoplasms
73
Carcinoma, Non-Small-Cell Lung
36
Carcinoma, Renal Cell
35
Prostatic Neoplasms
34
Colorectal Neoplasms
34
Lung Neoplasms
31
Melanoma
17
Multiple Myeloma
15
Ovarian Neoplasms
13
Urinary Bladder Neoplasms
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Neoplasm Metastasis
11
Lymphoma, Follicular
11
Colonic Neoplasms
11
Stomach Neoplasms
10
Lymphoma
10
Kidney Neoplasms
10
Hematologic Neoplasms
10
Rectal Neoplasms
9
Arthritis, Rheumatoid
9
Recurrence
8
Papillomavirus Infections
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
8
Pancreatic Neoplasms
7
Neoplasms, Plasma Cell
7
Lymphoma, Large B-Cell, Diffuse
7
COVID-19
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Clear all
NCT04285723
2023-02-09
EPIK-P1
Novartis
Completed
57 enrolled
23 charts
1 FDA